How to buy Cardiff Oncology stock | $8.4

Cardiff Oncology, Inc is a biotechnology business based in the US. Cardiff Oncology shares (CRDF) are listed on the NASDAQ and all prices are listed in US Dollars. Cardiff Oncology employs 11 staff and has a trailing 12-month revenue of around 0.00.

Cardiff Oncology stock price (NASDAQ: CRDF)

Use our graph to track the performance of CRDF stocks over time.

Cardiff Oncology shares at a glance

• Key figures

Information last updated 2021-07-22.

Latest market close	$8.40
52-week range	$4.29 - $25.50
50-day moving average	$7.16
200-day moving average	$9.88
Wall St. target price	$26.67
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-2.73

Buy Cardiff Oncology shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Cardiff Oncology stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Cardiff Oncology, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Cardiff Oncology price performance over time

Historical closes compared with the close of $8.4 from 2021-05-28

1 week (2021-07-18)	N/A
1 month (2021-06-29)	16.67%
3 months (2021-04-29)	-11.67%
6 months (2021-01-25)	N/A

1 year (2020-07-25)	N/A
2 years (2019-07-25)	N/A
3 years (2018-07-25)	N/A
5 years (2016-07-25)	N/A

Cardiff Oncology financials

Revenue TTM	$369,993
Gross profit TTM	$-10,869,403
Return on assets TTM	-17.77%
Return on equity TTM	-31.15%
Profit margin	0%
Book value	$3.32
Market capitalisation	$201.3 million

TTM: trailing 12 months

Shorting Cardiff Oncology shares

There are currently 3.2 million Cardiff Oncology shares held short by investors – that's known as Cardiff Oncology's "short interest". This figure is 25% up from 2.6 million last month.

There are a few different ways that this level of interest in shorting Cardiff Oncology shares can be evaluated.

Cardiff Oncology's "short interest ratio" (SIR)

Cardiff Oncology's "short interest ratio" (SIR) is the quantity of Cardiff Oncology shares currently shorted divided by the average quantity of Cardiff Oncology shares traded daily (recently around 681308.82352941). Cardiff Oncology's SIR currently stands at 4.76. In other words for every 100,000 Cardiff Oncology shares traded daily on the market, roughly 4760 shares are currently held short.

However Cardiff Oncology's short interest can also be evaluated against the total number of Cardiff Oncology shares, or, against the total number of tradable Cardiff Oncology shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Cardiff Oncology's short interest could be expressed as 0.09% of the outstanding shares (for every 100,000 Cardiff Oncology shares in existence, roughly 90 shares are currently held short) or 0.1097% of the tradable shares (for every 100,000 tradable Cardiff Oncology shares, roughly 110 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Cardiff Oncology.

Find out more about how you can short Cardiff Oncology stock.

Cardiff Oncology share dividends

We're not expecting Cardiff Oncology to pay a dividend over the next 12 months.

Have Cardiff Oncology's shares ever split?

Cardiff Oncology's shares were split on a 1:6 basis on 19 February 2019. So if you had owned 6 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Cardiff Oncology shares – just the quantity. However, indirectly, the new 500% higher share price could have impacted the market appetite for Cardiff Oncology shares which in turn could have impacted Cardiff Oncology's share price.

Cardiff Oncology share price volatility

Over the last 12 months, Cardiff Oncology's shares have ranged in value from as little as $4.289 up to $25.5. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cardiff Oncology's is 1.7933. This would suggest that Cardiff Oncology's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Cardiff Oncology overview

Cardiff Oncology, Inc. , a clinical-stage biotechnology company, develops drugs for the treatment of cancer. Its lead drug candidate is onvansertib, a Polo-like Kinase 1 selective adenosine triphosphate competitive inhibitor that is in Phase Ib/II clinical trial in acute myeloid leukemia (AML); has completed a Phase I clinical trial in advanced solid tumors; and Phase Ib/II clinical trial for metastatic colorectal cancer in combination with FOLFIRI and Avastin. The company's onvansertib is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer. In addition, it develops therapeutics, such as belinostat (Beleodaq); quizartinib (AC220), a development stage FLT3 inhibitor; and bortezomib (Velcade) for the treatment of leukemias, lymphomas, and solid tumor cancers. The company primarily serves pharmaceutical companies. Cardiff Oncology, Inc.

Frequently asked questions

What percentage of Cardiff Oncology is owned by insiders or institutions?
Currently 1.667% of Cardiff Oncology shares are held by insiders and 71.744% by institutions. How many people work for Cardiff Oncology?
Latest data suggests 11 work at Cardiff Oncology. When does the fiscal year end for Cardiff Oncology?
Cardiff Oncology's fiscal year ends in December. Where is Cardiff Oncology based?
Cardiff Oncology's address is: 11055 Flintkote Avenue, San Diego, CA, United States, 92121 What is Cardiff Oncology's ISIN number?
Cardiff Oncology's international securities identification number is: US14147L1089 What is Cardiff Oncology's CUSIP number?
Cardiff Oncology's Committee on Uniform Securities Identification Procedures number is: 897238101